Peter Thuss‐Patience
About
Peter Thuss‐Patience is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery.
According to data from OpenAlex, Peter Thuss‐Patience has authored 178 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 139 papers in Pulmonary and Respiratory Medicine, 98 papers in Oncology and 88 papers in Surgery. Recurrent topics in Peter Thuss‐Patience's work include Gastric Cancer Management and Outcomes (127 papers), Esophageal Cancer Research and Treatment (64 papers) and Gastrointestinal Tumor Research and Treatment (55 papers). Peter Thuss‐Patience is often cited by papers focused on Gastric Cancer Management and Outcomes (127 papers), Esophageal Cancer Research and Treatment (64 papers) and Gastrointestinal Tumor Research and Treatment (55 papers). Peter Thuss‐Patience collaborates with scholars based in Germany, Switzerland and United States. Peter Thuss‐Patience's co-authors include Peter Reichardt, Albrecht Kretzschmar, Guido Schumacher, Dmitry Bichev, Daniel Pink, Florian Lordick, Sylvie Lorenzen, Axel Hinke, Kirstin Breithaupt and Bernd Dörken and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.
In The Last Decade
Peter Thuss‐Patience
166 papers receiving 4.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peter Thuss‐Patience Germany | 33 | 2.9k | 2.2k | 1.7k | 927 | 313 | 178 | 4.3k | ||
| C.J.H. van de Velde Netherlands | 24 | 2.1k 0.7× | 1.7k 0.8× | 2.0k 1.1× | 1.0k 1.1× | 191 0.6× | 52 | 4.1k | ||
| Tae Sung Sohn South Korea | 34 | 3.2k 1.1× | 1.1k 0.5× | 1.7k 1.0× | 1.5k 1.7× | 159 0.5× | 127 | 4.3k | ||
| Richard F. Riedel United States | 26 | 1.9k 0.7× | 1.2k 0.5× | 734 0.4× | 906 1.0× | 130 0.4× | 110 | 3.4k | ||
| Fareeda Y. Coxon United Kingdom | 17 | 2.8k 1.0× | 1.8k 0.8× | 1.6k 0.9× | 1.0k 1.1× | 92 0.3× | 38 | 3.6k | ||
| Jae Moon Bae South Korea | 31 | 2.7k 0.9× | 987 0.4× | 1.4k 0.8× | 1.3k 1.4× | 179 0.6× | 132 | 3.9k | ||
| Ji Yeong An South Korea | 40 | 3.7k 1.3× | 1.2k 0.5× | 2.0k 1.1× | 1.9k 2.1× | 145 0.5× | 170 | 4.8k | ||
| Clare Peckitt United Kingdom | 31 | 1.8k 0.6× | 1.7k 0.8× | 1.1k 0.6× | 410 0.4× | 437 1.4× | 102 | 3.9k | ||
| Cornelis JH van de Velde Netherlands | 23 | 1.2k 0.4× | 1.7k 0.8× | 1.3k 0.7× | 306 0.3× | 210 0.7× | 46 | 3.5k | ||
| Jonathan Wadsley United Kingdom | 20 | 1.3k 0.4× | 1.2k 0.6× | 992 0.6× | 320 0.3× | 136 0.4× | 89 | 2.3k | ||
| Mahmut Gümüş Türkiye | 27 | 1.2k 0.4× | 2.2k 1.0× | 757 0.4× | 143 0.2× | 144 0.5× | 174 | 3.7k |
Countries citing papers authored by Peter Thuss‐Patience
Since
Specialization
Citations
This map shows the geographic impact of Peter Thuss‐Patience's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Thuss‐Patience with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Thuss‐Patience more than expected).
Fields of papers citing papers by Peter Thuss‐Patience
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Peter Thuss‐Patience. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Thuss‐Patience. The network helps show where Peter Thuss‐Patience may publish in the future.
Co-authorship network of co-authors of Peter Thuss‐Patience
This figure shows the co-authorship network connecting the top 25 collaborators of Peter Thuss‐Patience. A scholar is included among the top collaborators of Peter Thuss‐Patience based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Thuss‐Patience. Peter Thuss‐Patience is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Goldstein, David S., Katrin Marie Sjoquist, Sun Young Rha, et al.. (2025). LBA80 Regorafenib plus nivolumab vs investigator’s choice of chemotherapy in previously treated gastric or gastroesophageal cancer: INTEGRATE IIb, a randomized phase 3 AGITG Intergroup [NHMRC-CTC/IKF/AIO, ACCRU, TCOG/NHRI] study. Annals of Oncology. 36. S1622–S1623.
2.
Wittenbecher, Friedrich, Jörg Westermann, Peter Thuss‐Patience, et al.. (2024). Effective symptom relief through continuous integration of palliative care in advanced renal cell carcinoma patients: comprehensive measurement using the palliative care base assessment. Palliative Care and Social Practice. 18. 396558216–396558216.
3.
Al‐Batran, Salah‐Eddin, Sylvie Lorenzen, Jorge Riera, et al.. (2024). Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4001–LBA4001.
4.
Li, Moying, Nadja M. Meindl‐Beinker, Johannes Betge, et al.. (2024). Functional status and quality of life in older patients with advanced esophageal squamous cell cancer receiving second-line nivolumab ± ipilimumab therapy: A post hoc analysis of the phase 2, multicenter RAMONA study. Journal of Geriatric Oncology. 15(7). 101838–101838.
5.
Thuss‐Patience, Peter, Eray Goekkurt, M. Stahl, et al.. (2024). Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma. JAMA Network Open. 7(1). e2352830–e2352830.
6.
Ettrich, Thomas J., Regine Mayer‐Steinacker, Stephan Stilgenbauer, et al.. (2024). SOP – Darmpassagestörung in der Palliativmedizin.
7.
Lordick, Florian, Peter Thuss‐Patience, Michael Bitzer, et al.. (2023). Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. Journal of Cancer Research and Clinical Oncology. 149(9). 5937–5950.
8.
Ajani, Jaffer A., Farid El Hajbi, David Cunningham, et al.. (2023). Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open. 9(1). 102202–102202.
9.
Lordick, Florian, Salah‐Eddin Al‐Batran, Dirk Arnold, et al.. (2023). German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 27(1). 6–18.
10.
Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2023). O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG. Annals of Oncology. 34. S182–S182.
11.
Lorenzen, Sylvie, Peter Thuss‐Patience, Claudia Pauligk, et al.. (2022). FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. European Journal of Cancer. 165. 48–57.
12.
Panje, Cédric, Stefanie Hayoz, Wolfgang Eisterer, et al.. (2022). Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial. European Journal of Cancer. 177. 186–193.
13.
Harbeck, Nadia, Andreas Schneeweiß, Peter Thuss‐Patience, et al.. (2021). Neoadjuvant and adjuvant end-points in health technology assessment in oncology. European Journal of Cancer. 147. 40–50.
14.
Hofheinz, Ralf‐Dieter, S. Hegewisch-Becker, Volker Kunzmann, et al.. (2021). Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. International Journal of Cancer. 149(6). 1322–1331.
15.
Wagner, Dorothea, Heike I. Grabsch, Murielle Mauer, et al.. (2019). EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 19(1). 494–494.
16.
Lordick, Florian, Salah‐Eddin Al‐Batran, Manfred Dietel, et al.. (2017). HER2 testing in gastric cancer: results of a German expert meeting. Journal of Cancer Research and Clinical Oncology. 143(5). 835–841.
17.
Thuss‐Patience, Peter, et al.. (2017). End-of-life care for immigrants in Germany. An epidemiological appraisal of Berlin. PLoS ONE. 12(8). e0182033–e0182033.
18.
Thuss‐Patience, Peter, Manish A. Shah, Atsushi Ohtsu, et al.. (2017). Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. The Lancet Oncology. 18(5). 640–653.
19.
Lordick, Florian, Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, et al.. (2016). HER2-Testung beim Magenkarzinom – Ergebnisse eines deutschen Expertentreffens. Zeitschrift für Gastroenterologie. 54(8). 791–796.
20.
Baretton, Gustavo, Manfred Dietel, Timo Gaiser, et al.. (2016). HER2-Testung beim Magenkarzinom. Der Pathologe. 37(4). 361–366.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by C.J.H. van de Velde Breakdown of academic impact, for papers by Tae Sung Sohn Breakdown of academic impact, for papers by Richard F. Riedel Breakdown of academic impact, for papers by Fareeda Y. Coxon Breakdown of academic impact, for papers by Jae Moon Bae Breakdown of academic impact, for papers by Ji Yeong An Breakdown of academic impact, for papers by Clare Peckitt Breakdown of academic impact, for papers by Cornelis JH van de Velde Breakdown of academic impact, for papers by Jonathan Wadsley Breakdown of academic impact, for papers by Mahmut Gümüş